Despite these disparities, our data demonstrate the potent activity and versatility of AnxA1Ac2-26 to mitigate both LPS- and SCD-associated cerebral thrombosis (in both arterioles and venules) in an Fpr2/ALX-dependent manner. Here, FPR2 is linked to deep vein thrombosis.